Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study [Yahoo! Finance]
Aura Biosciences, Inc. (AURA)
Company Research
Source: Yahoo! Finance
Shares of Aura Biosciences AURA gained 7.9% on Sept. 12 after the company announced encouraging data from a phase II study evaluating its lead candidate, bel-sar (AU-011), to treat early-stage choroidal melanoma (CM) in the first-line setting. Bel-sar is a novel investigational agent designed with a dual mechanism of action that includes targeted cytotoxicity and immune activation. CM is a type of cancer occurring in the choroid, a layer of blood vessels and connective tissue between the sclera (white of the eye) and retina. It is the most common primary intraocular (inside the eye) cancer in adults. Bel-Sar Leads to Tumor Control & Preserves Visual Acuity The phase II study results showed that bel-sar achieved an 80% tumor control rate in phase III-eligible patients (8 out of 10) who received the treatment. Among these responders, the tumor stopped growing completely. 90% of the patients preserved their visual acuity. This is particularly important since 80% of these patients
Show less
Read more
Impact Snapshot
Event Time:
AURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AURA alerts
High impacting Aura Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
AURA
News
- Aura Biosciences, Inc. (NASDAQ: AURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.MarketBeat
- Aura Biosciences Reports Third Quarter 2024 Financial Results and Business HighlightsGlobeNewswire
- Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value [Seeking Alpha]Seeking Alpha
- Aura Biosciences, Inc. (NASDAQ: AURA) had its "buy" rating re-affirmed by analysts at Cowen Inc.MarketBeat
- Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at Scotiabank from $20.00 to $23.00. They now have a "sector outperform" rating on the stock.MarketBeat
AURA
Earnings
- 11/12/24 - Beat
AURA
Sec Filings
- 11/18/24 - Form 4
- 11/18/24 - Form 144
- 11/14/24 - Form SC
- AURA's page on the SEC website